Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype

J Allergy Clin Immunol. 2021 Jan;147(1):403-405. doi: 10.1016/j.jaci.2020.04.056. Epub 2020 May 19.

Abstract

All fifteen patients with HLA-A*32:01 restricted vancomycin-induced DRESS, showed negative ex vivo responses to dalbavancin however two showed cross-reactivity to teicoplanin and telavancin. Adjunctive diagnostic testing should be considered to detect potential cross-reactivity amongst glycopeptides.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminoglycosides / administration & dosage
  • Aminoglycosides / adverse effects*
  • Drug Hypersensitivity Syndrome / genetics*
  • Drug Hypersensitivity Syndrome / immunology
  • HLA-A Antigens / genetics*
  • HLA-A Antigens / immunology
  • Haplotypes*
  • Humans
  • Lipoglycopeptides / administration & dosage
  • Lipoglycopeptides / adverse effects*
  • Teicoplanin / administration & dosage
  • Teicoplanin / adverse effects*
  • Vancomycin / administration & dosage
  • Vancomycin / adverse effects*

Substances

  • Aminoglycosides
  • HLA-A Antigens
  • HLA-A*32 antigen
  • Lipoglycopeptides
  • Teicoplanin
  • Vancomycin
  • telavancin